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Summary The purpose of this study was to assess the usefulness of ultrasonography (US) in the assessment ofthe breastfollowing primary
medical therapy (PMT) of large operable breast cancer. A total of 52 patients were studied; all had invasive breast cancer, confirmed by core
biopsy, with initial size > 4 cm by palpation, T2-3, NO-1, MO. PMT was with epirubicin, cisplatin and continuous infusional 5-fluorouracil, as
previously described (Jones et al, 1994, J Clin Oncol 12: 1259-1265). Independent clinical and US assessments were made during PMT
before surgery or biopsy. A total of 31 (60%) patients achieved complete clinical response (cCR), but in only five of these was the post-
treatment ultrasound normal. Post-treatment sonographic findings of diffuse parenchymal distortion or a mass lesion without Doppler signal
were associated with more favourable histology (pathological CR, non-invasive or microinvasive carcinoma), whereas a mass with Doppler
positivity was more often associated with residual macroscopic invasive carcinoma. Patients who did not achieve cCR had a high incidence
of residual macroscopic carcinoma (71%) regardless of the sonographic characteristics. With median follow-up of 27 months (range 12-43),
ten (19%) patients have relapsed and six (12%) have died, but only one relapse has occurred within treated breast. Ultrasonography is a
sensitive technique for assessing the response to PMT, particularly in patients who achieve cCR. It may be helpful in selecting those patients
who do not require post-PMT surgery and in localizing abnormalities in those who do, particularly in those with cCR. However, clinicians
should be aware that a residual US abnormality is by no means pathognomonic of residual cancer.
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The current standard management of a patient with large operable
breast cancer is immediate mastectomy followed by adjuvant
medical therapy. As an alternative, several groups are investi-
gating primary medical (or 'neoadjuvant') therapy (PMT): imme-
diate drug therapy with surgery deferred until later (Bonadonna et
al, 1990; Fisher et al, 1994; Smith et al 1995; Powles et al, 1995).
Reversal of the conventional sequence of treatments may have
several potential advantages, including regression of the primary
tumour and a reduced need for subsequent mastectomy (Powles et
al, 1995; Smith et al, 1995). High response rates, with complete
clinical remission rates ofup to 60%, canbe achieved even in large
primary cancers by the use ofmoderately dose-intensive infusion-
based chemotherapy regimens not requiring growth factor or
progenitor cell support (Smith et al, 1995).
After PMT a decision must be made about the extent, if any, of
surgery to be recommended. Here, opinions and policies vary
widely. In the recent USA National Surgical Adjuvant Breast and
Bowel Project (NSABP) B-18 trial of primary chemotherapy, the
extent of surgery was left to the discretion ofthe treating surgeon:
19% of patients who had achieved clinical CR, and 39% of those
with partial response (PR), still underwent mastectomy, whereas
50% of those with no change or progressive disease had breast-
conserving operations (Fisher et al, 1994). In other series, patients
who have achieved clinical CR are treated with radiotherapy alone
(Smith et al, 1995), whereas others have omitted surgery even in
patients with only partial response after primary chemotherapy,
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deferring the decision until after radiotherapy (Weil et al, 1995).
The final arbiter ofthese approaches will be the eventual rate of
uncontrolled local recurrence - a late end point requiring several
years of follow-up. Meanwhile, one logical approach is to assess
as accurately as possible the extent of residual disease at the
completion of chemotherapy and to base decisions upon that
assessment.
Methods of assessment of response to therapy other than clin-
ical examination include mammography and ultrasound. Baseline
mammography provides initial information aboutthe presence and
extent of malignant calcification and also the presence of multi-
focal or contralateral carcinoma. However, as a method for
assessing response to PMT it is less useful, as continuing mammo-
graphic density and calcification are common and correlate poorly
with pathological findings (Moskovic et al, 1993).
Ultrasound is fast, safe, widely available and inexpensive. With
the introduction of high-frequency, high-resolution transducers it
has become an effective and increasingly used method for the
primary assessment and follow-up ofbreast cancer (Balu-Maestro
et al, 1991; Forouhi et al 1994; Tohno et al, 1994; Gawne-Cain et
al, 1995). In addition, various workers have recently described
the use of colour Doppler ultrasonography as an adjunct in the
diagnosis of breast cancer by detecting malignant neovascularity
both in the primary tumour and in axillary lymphadenopathy
(Castagnone et al, 1993; Grishke et al, 1994; Kedar et al, 1994;
Walsh et al, 1994). All these features make serial ultrasound scan-
ning a useful method ofmonitoring response to chemotherapy, but
the interpretation of residual sonographic abnormalities after
treatment remains uncertain.
Accordingly, this study was undertaken to determine the role
of ultrasound in monitoring response to primary, in particular, to
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Table 1 Patient characteristics (n = 52)
Age
Menses
Premenopausal
Peri/post-menopausal
Surgical assessment at presentation
Operable by mastectomy
Suitable for conservation
Clinical TNM staging
T2 (but > 4 cm)
T3
T4 (operable)
NO
Ni
MO
26-60 years (median 45)
34
18
52
0
19
29
4
30
22
52
(minimal staging)
Histology (pretreatment core-cut biopsy)
Grade 1
Grade 2
Grade 3
Insufficient for grading
17
22
12
Table 2 Clinical and sonographic response to PMT
Clinical response Total
CR PR NC
US response
CR 5 - - 5 (10%)
PR 25 15 - 40 (77%)
NC 1 5 1 7 (13%)
Total 31 20 1 52
(60%) (38%) (2%) (100%)
Table 3 Clinical and pathological response to PMT
Clinical response Total
CR PR NC
Pathological response
Notdone 7 - - 7 (13%)
pCR 9a - 9 (17%)
Non-invasive/
microinvasive 8 6 - 14 (27%)
Macroinvasive
carcinoma 7 14 1 22 (42%)
Total 31 20 1 52
(60%) (38%) (2%) (100%)
aof the nine pCRs, four were diagnosed from multiple core-cut biopsies, five
from wide local excision.
improve our understanding of the nature of residual sonographic
abnormalities at the end ofchemotherapy.
PATIENTS AND METHODS
Over the past 3 years, patients under 65 years old presenting to the
Royal Marsden Hospital with large (.4 cm), operable primary
breast cancer have participated in a programme of primary
medical therapy (PMT). A total of52 such patients have been seri-
ally assessed by manual palpation and by colour Doppler ultra-
sound, and form the basis ofthis report. Their characteristics, and
the characteristics oftheir tumours, are given in Table 1.
Treatment and assessment protocol
In all cases, the diagnosis ofinvasive carcinoma was confirmedby
core-cut needle biopsy before initiating treatment. PMT consisted
of epirubicin, cisplatin and protracted infusional 5-fluorouracil
(ECisF) as previously described (Jones et al, 1994; Smith et al,
1995), for 6-8 cycles of 21 days. In brief, this regimen comprises
epirubicin 50-60 mg m-2 and cisplatin 60 mg m-2 on day 1, with
continuous ambulatory venous infusion of 5-fluorouracil
200 mg m-2 per 24 h throughout the cycle (days 1-21).
Bidimensional estimation of tumour size was made by a senior
clinician using callipers before each cycle of chemotherapy (i.e.
3-weekly) and at the end of treatment. Ultrasonography was
performed before treatment and 6-weekly thereafter. Although these
assessments were not formally 'blinded', clinical assessments were
routinely performed without knowledge of that day's ultrasound
result and vice versa. Mammography was performed before treat-
mentbut, afterworkwithinthe unitthat showedlittle value ofserial
mammography in this circumstance (Moskovic et al, 1992), serial
and post-treatmentmammography were notroutinely performed.
After primary medical therapy, patients were treated according
to the residual abnormality. Those with no palpable abnormality
were eligible to be treated with radiotherapy alone, although in
most cases if a residual area of abnormality was detectable on
ultrasound this was first widely excised under US-guided needle
localization, or biopsied with multiple core-cut biopsies. Those
with a residual palpable abnormality were subjected to either
breast-conserving surgery or mastectomy according to the normal
surgical criteria of size and position. Patients undergoing breast
surgery also had level 2 axillary dissection.
All patients who had not undergone mastectomy received radio-
therapy to theresidual breasttissue. Thosewhohad nothad axillary
dissection alsoreceivedradiotherapytothe axilla. Othernodal areas
were not routinely irradiated. All patients regardless of age,
menstrual status and hormone receptor status received adjuvant
tamoxifen 20 mg o.d. for2 years fromcompletion ofchemotherapy.
Ultrasound technique
Patients were scanned using a 7-MHz hand-held linear array
transducer attached to an Acuson 128 computed sonography unit
(Mountain View, CA, USA). Measurements of the tumour size
(cm) in three orthogonal planes were obtained using real-time
ultrasound and then the mass was assessed for colour Doppler
signals. The Acuson capability for colour Doppler (5 MHz) was
used for flow evaluation using the standardized machine settings.
These settings were chosen to optimize sensitivity to low velocity
and low-volume blood flow. Doppler positivity was ascribed if
colour Doppler signals were obtained within 5 mm of the margin
ofthe tumour or inside it. In addition, a visual score from 0 to 3 of
the vascularity of the tumour provided by the colour Doppler
signal was made at each scan.
After therapy, in the case of sonographic resolution of the
primary breast tumour, the presence, appearance and measure-
ments of any residual parenchymal distortion are recorded with
any associated Doppler signal, ifpresent.
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Figure 1 (A) and (B) Pre- and post-treatment ultrasound appearances. This patient's tumour underwent clinical complete response. The residual sonographic
abnormality (B) is a small area of parenchymal distortion (arrowed) from multiple core-cut biopsies were obtained under ultrasound guidance. (C) Histology
showing foci of degenerate atypical cells highly suggestive of residual carcinoma
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Response criteria
For clinical and sonographic criteria, the UICC designations of
treatment response were used, i.e. CR (complete response), no
detectable tumour; PR (partial response), 2 50% reduction in
bidimensional product; NC (no change), reduction of < 50% or
increase of <25% in bidimensional product; PD (progressive
disease), increase of 2 25% in tumour bidimensional product. A
clinical finding of 'vague thickening' in the vicinity of the breast
previously occupied by tumour was scored as PR, as was the sono-
graphic finding of 'vague parenchymal distortion'.
RESULTS
The clinical and sonographic response rates are shown in Table 2.
The ECisF chemotherapy regimen produced a high clinical CR
(cCR) rate of 60%, but ultrasonographic abnormalities remained
in the majority of these patients. A consistent finding in the
general appearance ofthe post-treatment breast on ultrasound was
the presence of diffusely echogenic tissue at the site of previous
tumour and surrounding any residual tumour, which effaced the
normal parenchymal echopattern locally. This brightly reflecting
tissue appeared to correspond to hyalinized fibrofatty tissue seen
pathologically in association with the region oftreated tumour.
Post-treatment histological findings in 45 patients are shown in
Table 3. Pathological CR (pCR) was found in nine, with a further
14 patients showing abnormalities not amounting to residual inva-
sive tumour masses (scattered atypical cells in five; DCIS in four;
microinvasion in five). The remaining 22 patients had residual
invasive tumour masses.
The contribution of ultrasound in patients without cCR
Twenty-one patients had palpable abnormalities at the end oftreat-
ment. In every case, surgery was performed (wide local excision
in 18; mastectomy in three). DCIS alone was found in three,
and microinvasion in two. The remaining 16 operative specimens
contained residual macroscopic invasive cancers, although in five
cases the residual disease was of a lower grade than the pretreat-
ment biopsy.
In all 21 patients with palpable residual disease, a measurable
sonographic lesion was also present. However, the ultrasound
findings, including Doppler signal, were not helpful in distin-
guishing those patients with macroscopic invasive cancers from
those with lesser histological findings (Table 4). Nor was ultra-
sound superior to clinical assessment in predicting the maximum
diameter ofthe excised tumour (data not shown).
Table 4 Ultrasound and pathological finding in patients without clinical CR
Patients without clinical US findings
CR (n = 21)
PR mass PR mass NC mass
Doppler - Doppler + Doppler +
Pathological response
Non-invasive/microinvasive 3 3 -
Macroinvasive carcinoma 6 3 6
The contribution of ultrasound in patients with cCR
Ofthe 31 patients with cCR, 15 underwent US-assisted wide local
excision of sonographic abnormalities and nine had multiple US-
guided core-cut biopsies (seven went on to radiotherapy without
biopsy). Histology in these 24 patients showed residual macro-
scopic invasive cancer in six, microinvasion or scattered suspi-
cious cells in six, DCIS in two, and no evidence ofdisease in ten.
Table 5 shows the ultrasound and histological findings in these
women.
The significance of normalization of the ultrasound (uCR) was
not determined in this study. This occurred in five patients, but in
only one was biopsy undertaken -using multiple core-cutbiopsies
of the previously affected segment. These showed no evidence
of disease. Other patients with uCR proceeded to radiotherapy
without biopsy.
In five patients the post-treatment ultrasound showed a residual
area of diffuse parenchymal abnormality without Doppler signal.
Histological findings in these patients varied from pCR in one
patient to scattered degenerate carcinoma cells in three patients, to
frank residual carcinoma in one patient. Figure 1 shows represen-
tative appearances in a patient with cCR whose post-treatment
ultrasound showed diffuse parenchymal distortion. When multiple
core-cut biopsies were obtained from this area, they showed
microscopic foci of scattered degenerate atypical cells indicating
residual carcinoma.
The remaining 21 patients with cCR had measurable residual
mass lesions on ultrasound (Table 5). The presence of Doppler
signal appeared to predict for residual disease in these patients:
five out ofsix patients with Doppler positivity had residual cancer
or DCIS on histology. On the other hand, among patients with
Doppler-negative mass lesions, 7 out of 12 had pCR.
DISCUSSION
The initial results of primary medical therapy (PMT) for large
operable breast cancer are encouraging: the technique appears to
enable breast-conserving treatment to be offered to a majority of
the women who currently require mastectomy. The early results of
our series and others suggest that this is not at the cost of a high
rate oflocal relapse. It is not yet known whether PMT also confers
an advantage in terms oflong-term systemic control and survival;
this question has been addressed in ongoing randomized trials by
the NSABP, the EORTC and others. However, even if these trials
were to show no overall survival advantage for PMT, the benefits
Table 5 Ultrasound and pathological findings in patients with clinical CR
Patients with clinical US findings
CR (n = 31)
CR Parenchymal PR mass PR/NC mass
distortion Doppler - Doppler +
Pathological response
Notdone 4 - 2 1
pCR 1 1a 7b 1
Non-invasive/microinvasive - 3 2 3
Macroinvasive carcinoma - 1 3 2
aDiagnosed by multiple core-cut biopsies. bOf the seven pCRs, four were
diagnosed from multiple core-cut biopsies, three from wide local excision.
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of breast conservation will probably ensure continued interest in
the approach.
In the authors' experience, PMT 'has been made more
practicable by the development of the highly effective ECisF
chemotherapy regimen. This has permitted the treatment of
patients with large tumours, at the borderline ofoperability, with a
negligible risk ofprogressive disease during treatment and a high
probability of clinical complete response (cCR). A multicentre
randomized trial is under way in the UK comparing this new
regimen with aconventional chemotherapy schedule (doxorubicin,
cyclophosphamide; AC) as PMT for operable breast cancer.
The use of chemotherapy to shrink primary tumours leads to
new, welcome but difficult decisions in subsequent surgical
management. The key questions are: what is the minimum and
most conservative surgery that may be performed (with post-oper-
ative radiotherapy), without risk of local relapse, after a large
tumour has been 'downsized' by PMT; and under what circum-
stances might surgery be omitted altogether?
The current working assumption of our unit and others is that,
after primary chemotherapy, residual invasive carcinoma, micro-
invasive carcinoma or carcinoma in situ should be widely resected
and the breast subsequently irradiated. Conversely, patients with
pathological CR might safely be treated with radiotherapy alone.
However, it is not known whether these assumptions are correct.
Treatment ofprimary DCIS with radiotherapy is an accepted alter-
native to mastectomy, forming an arm of current trials, and a
similar approach might reasonably be considered with non-
invasive carcinoma, or even microinvasive carcinoma, after
primary chemotherapy.
The use of histological criteria for guiding post-PMT manage-
ment raises its own problems. In this study, a compromise was
reached between the certainty ofthe histological diagnosis and the
demands ofbreast conservation. For those patients in whom PMT
was mosteffective and the tumour site was no longer easily identi-
fiable after treatment, an extensive resection would have been
required for full histological assessment. Instead, we used the
approach of more limited sampling with multiple core-cut biop-
sies, or in some cases no biopsy. Inevitably, this limits the confi-
dence of our histological response rate. Some other centres use
skin tattooing or inject carbon or metal markers into the tumour at
the start oftreatment in order to allow selective biopsy ofthe area
after PMT (Veronesi et al, 1995).
The potential role of ultrasound in post-chemotherapy assess-
ment is to help select, in cases where there is clinical doubt, those
patients who do or do not require excision, and to localize lesions
in those who do.
For patients who had a residual palpable tumour or 'thickening'
at the end of PMT, we found that US contributed little. All these
patients had residual pathological lesions that by our current
criteria required excision, although in six cases these did not
amount to macroscopic invasive carcinoma. In all cases, sono-
graphic lesions persisted, but the sonographic findings (including
Doppler positivity) were not required for localization, did not
contribute to the surgical decision and did not identify the patients
with only non-invasive or microinvasive residual disease.
In patients with clinical CR (cCR), ultrasound proved a more
useful investigation. The majority (84%) ofpatients with cCR had
residual sonographic abnormalities; ultrasound is a useful tech-
nique for localization in these patients, but does it predict the
pathological findings and identify a group who may not require
surgery? Of the 23 such patients who underwent guided excision
or biopsy, nine (39%) proved to have pathological CR (pCR) and
in all but one of these patients the sonographic findings had been
of small, Doppler-negative lesions or parenchymal distortion
rather than a Doppler-positive mass. However, these 'favourable'
sonographic features were also seen in nine otherpatients who did
not have pCR. The small group ofpatients with complete resolu-
tion of the sonographic abnormality (uCR) probably represent
those with the most favourable response to PMT. Histological
assessment of these patients was not undertaken in this study, for
the reasons already discussed, but it seems reasonable to adopt the
approach that patients with sonographic CR have thehighest prob-
ability of pCR or minimal residual disease and are adequately
managed with radiotherapy alone.
In this study, the strength of colour Doppler positivity (i.e.
vascularity) was assessed visually but not quantitatively. This may
have limited our ability tocorrelate Dopplerfindings with ultimate
histology. Other workers, who have measured Doppler positivity
quantitatively using colour-capture techniques, have recently
reported excellent correlation between the reduction in sono-
graphic tumour size and the reduction in Doppler signal during
primary medical therapy (Kedar et al, 1994). This and other new
refinements in ultrasound technology may be useful for the detec-
tion ofabnormal low-velocity flow in vessels. A recent report has
shown dedicated breast magnetic resonance imaging (RODEO
MRI) to be a promising technique for prediction of pathological
response to primary chemotherapy (Abraham et al, 1996), and a
comparison ofthese techniques would be interesting.
The next step in rationalizing decisions about treatment after
PMT must involve randomization between different approaches.
Forexample, patients with cCR after PMTcould be randomized to
have radiotherapy alone or US-guided wide local excision plus
radiotherapy. The reference of ultrasound assessment will be
determined by long-term follow-up from such randomized trials.
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